Retatrutide Has a Public Sequence — Your Lab Still Needs a Trusted Lot
PeptideLab Editorial
편집팀
Not Lilly’s investigational product. RUO retatrutide is for qualified research only — not human injection or weight-loss treatment.
Retatrutide (GLP-1 + GIP + glucagon receptor activity) is described in patent and trial literature with defined modifications — including lipidation chemistry that is easy to get wrong in synthesis.
“Open sequence” ≠ interchangeable quality
Many suppliers can quote the same amino-acid string. What breaks assays:
- Incorrect fatty-acid conjugation site or chain length
- Deletion sequences and unremoved protecting groups
- Oxidation during storage or poor lyophilization
What to demand before an animal arm
- COA with HPLC chromatogram and numeric purity
- MS within expected error for the modified peptide
- Stability note for lyophilized cake and reconstitution for in-vitro buffers only
Transparency builds citations
When reviewers ask how reference material was qualified, “purchased online” is not enough. Archive supplier COA with your protocol registration.
Explore retatrutide in our catalog and the dedicated transparency section on our homepage.